These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 28695683)
1. Combinations of single nucleotide polymorphisms WWOX-rs13338697, GALNT14-rs9679162 and rs6025211 effectively stratify outcomes of chemotherapy in advanced hepatocellular carcinoma. Lin WR; Hsu CW; Yeh CS; Chen YC; Chang ML; Liang KH; Lin CC; Chu YD; Yeh CT Asia Pac J Clin Oncol; 2018 Apr; 14(2):e54-e63. PubMed ID: 28695683 [TBL] [Abstract][Full Text] [Related]
2. A single nucleotide polymorphism on the GALNT14 gene as an effective predictor of response to chemotherapy in advanced hepatocellular carcinoma. Yeh CT; Liang KH; Lin CC; Chang ML; Hsu CL; Hung CF Int J Cancer; 2014 Mar; 134(5):1214-24. PubMed ID: 23959947 [TBL] [Abstract][Full Text] [Related]
4. A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy. Lin CC; Hsu CW; Chen YC; Chang ML; Liang KH; Lai MW; Lin CL; Chien RN; Lin KH; Yeh CT Pharmacogenomics J; 2020 Feb; 20(1):57-68. PubMed ID: 31611591 [TBL] [Abstract][Full Text] [Related]
5. GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Liang KH; Lin CC; Yeh CT Pharmacogenomics; 2011 Jul; 12(7):1061-73. PubMed ID: 21635146 [TBL] [Abstract][Full Text] [Related]
6. Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib. Lin CL; Chien RN; Chen LW; Chu YD; Yeh CT Cancer Biomark; 2023; 36(3):251-266. PubMed ID: 36938726 [TBL] [Abstract][Full Text] [Related]
7. GALNT14-mediated O-glycosylation on PHB2 serine-161 enhances cell growth, migration and drug resistance by activating IGF1R cascade in hepatoma cells. Chu YD; Fan TC; Lai MW; Yeh CT Cell Death Dis; 2022 Nov; 13(11):956. PubMed ID: 36376274 [TBL] [Abstract][Full Text] [Related]
8. GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy. Lin WR; Chiang JM; Liang KH; Lim SN; Lai MW; Tsou YK; Hsieh TY; Hsu CK; Yeh CT Medicine (Baltimore); 2016 Apr; 95(17):e3487. PubMed ID: 27124048 [TBL] [Abstract][Full Text] [Related]
9. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Chen WT; Lin SM; Lee WC; Wu TJ; Lin CC; Shen CH; Chang ML; Lin CL; Yeh CT Hepatol Int; 2022 Feb; 16(1):148-158. PubMed ID: 34982369 [TBL] [Abstract][Full Text] [Related]
13. GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Liang KH; Lin CL; Chen SF; Chiu CW; Yang PC; Chang ML; Lin CC; Sung KF; Yeh C; Hung CF; Chien RN; Yeh CT Pharmacogenomics; 2016 Mar; 17(4):353-66. PubMed ID: 26871639 [TBL] [Abstract][Full Text] [Related]
14. Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma. Zhan S; Qiu M; Wei X; Wei J; Qin L; Jiang B; Wen Q; Chen P; Lin Q; Wei X; Zhou Z; Jiang Y; Liang X; Li R; Liu Y; Yu H Cancer Med; 2024 Jan; 13(1):e6848. PubMed ID: 38151984 [TBL] [Abstract][Full Text] [Related]
15. IL-28B variant as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Terashima T; Honda M; Toyama T; Shimakami T; Shimizu R; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S J Gastroenterol Hepatol; 2020 Oct; 35(10):1813-1820. PubMed ID: 32180251 [TBL] [Abstract][Full Text] [Related]
16. Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer. Schirmer MA; Lüske CM; Roppel S; Schaudinn A; Zimmer C; Pflüger R; Haubrock M; Rapp J; Güngör C; Bockhorn M; Hackert T; Hank T; Strobel O; Werner J; Izbicki JR; Johnsen SA; Gaedcke J; Brockmöller J; Ghadimi BM J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26857392 [TBL] [Abstract][Full Text] [Related]
17. MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy. Hu W; Huang S; Dong L; Yu C; Li C; Zhang J Anticancer Drugs; 2019 Mar; 30(3):233-240. PubMed ID: 30779721 [TBL] [Abstract][Full Text] [Related]
18. A long non-coding RNA TSLD8 inhibits hepatocellular carcinoma by stabilizing WWOX. Xu F; Wang B; Liu M; Liu T; Zhang R Biochem Biophys Res Commun; 2019 Aug; 516(2):526-532. PubMed ID: 31230746 [TBL] [Abstract][Full Text] [Related]
19. Association of rs9679162 Genetic Polymorphism and Aberrant Expression of Polypeptide Lin NC; Shih YH; Chiu KC; Li PJ; Yang HW; Lan WC; Hsia SM; Wang TH; Shieh TM Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077753 [TBL] [Abstract][Full Text] [Related]
20. Thymidylate synthase gene polymorphisms as important contributors affecting hepatocellular carcinoma prognosis. Wang X; Sun X; Du X; Zhou F; Yang F; Xing J; Dong G; Guo X Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):319-326. PubMed ID: 28043790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]